



## PRESS RELEASE

innate pharma

---

### INNATE PHARMA UPDATES ON ITS NEXT MEETINGS WITH ANALYSTS AND INVESTORS

Marseilles, France, June 5, 2007

---

Innate Pharma S.A. (the "Company"), a biopharmaceutical company developing new drug classes targeting innate immunity, announces it will participate to the following analyst and investor conferences during the month of June:

- **BioFinance Europe, London, June 18, 2007:** in the context of this conference, organised by BIA, the UK trade association of biotechnology companies, Innate Pharma is invited to participate to a panel discussing different European IPO strategies.
- **PiperJaffray's second annual healthcare conference, London, June 21, 2007:** Innate Pharma is invited by PiperJaffray, an investment bank, to present the Company to investors invited by the bank.
- **First financial analysts and biotechnology companies' meeting organised by France Biotech**, the French trade association of biotechnology companies, **and the SFAF**, the French society of financial analysts, **Paris, June 28, 2007:** Innate Pharma is invited to present the Company to French financial analysts, in a meeting it has contributed to organise.

Ahead of its annual general meeting of shareholders, Innate Pharma will also have an information meeting open to analysts, investors and journalists on June 26, 2007, at 10 am in Marseilles. The venue will be the "New Hotel of Marseille", 71 Boulevard Charles Livon (F-13007 Marseilles).



## PRESS RELEASE

**innate** pharma

---

### About Innate Pharma:

Founded in 1999 and funded by reference venture capitalists up to its IPO on Euronext in Paris in 2006, Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH) is a biopharmaceutical company developing first-in-class\* drugs targeting innate immunity.

The pioneering work of Innate Pharma's scientific founders and research groups has led to the development of three product platforms (gamma delta T cells, NK cells and TLR), each directly or indirectly validated in clinical oncology settings.

Besides cancer, Innate Pharma's drug candidates have development potential in the treatment of infectious disease and chronic inflammation. The company's most advanced molecule is in Phase II clinical trials in cancer.

With its strong scientific position in innate immunity pharmacology, its robust intellectual property portfolio and its R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing immunotherapeutics market.

Based in Marseilles, France, Innate Pharma had 74 employees as at March 31, 2007.

Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com)

### Practical Information about Innate Pharma shares:

<b>ISIN code</b>	FR0010331421
<b>Ticker code</b>	IPH

### Disclaimer:

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

### For any additional information, please contact:

#### **Innate Pharma**

Stéphane Boissel, EVP and CFO  
Tel. : +33 (0)4 96 19 05 58  
[stephane.boissel@innate-pharma.fr](mailto:stephane.boissel@innate-pharma.fr)

#### **Alize Public Relations**

Caroline Carmagnol  
Tel. : +33 (0)6 64 18 99 59  
[caroline.carmagnol@wanadoo.fr](mailto:caroline.carmagnol@wanadoo.fr)

---

\* with new mechanisms of action.